Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry

Gut

Volumn 64, Issue 8, 2015, Pages 1192-1199

  Haidry, R J ^a,b   Butt, M A ^a   Dunn, J M ^c,d   Gupta, A ^b   Lipman, G ^a   Smart, H L ^e   Bhandari, P ^f   Smith, L ^g   Willert, R ^h   Fullarton, G ⁱ   Di Pietro, M ^j   Gordon, C ^k   Penman, I ^l   Barr, H ^m   Patel, P ⁿ   Kapoor, N ^o   Hoare, J ^p   Narayanasamy, R ^q   Ang, Y ^r   Veitch, A ^s   Ragunath, K ^t   Novelli, M ^b   Lovat, L B ^a,b   Banks, Matthew ^b   Sehgal, Vinay ^b   Graham, David ^b   Sweis, Rami ^b   Miah, Haroon ^b   Morris, Danielle ^b   Boger, Philip ⁿ   Morris, John ⁱ   O'Toole, Dermot ^q   Cheong, Edward ^u   Direkze, Natalie ^v   Dhar, Anjan ^w   Nylander, David ^x   Mahon, Brinder ^y   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF OSLO   (Norway)

^e ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^f ALEXANDRA HOSPITAL   (United Kingdom)

^g BRADFORD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^h MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

ⁱ GLASGOW ROYAL INFIRMARY   (United Kingdom)

^j ADDENBROOKE S HOSPITAL   (United Kingdom)

^k ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^l ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^m GLOUCESTERSHIRE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

ⁿ UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^o UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^p NATIONAL HEALTH SERVICE   (United Kingdom)

^q ST JAMES S HOSPITAL   (Ireland)

^r UNIVERSITY OF MANCHESTER   (United Kingdom)

^s ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^t NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^u NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^v FRIMLEY PARK HOSPITAL   (United Kingdom)

^w Department of Occupational Health and Wellbeing   (United Kingdom)

^x NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^y QUEEN ELIZABETH HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; COHORT ANALYSIS; CONTROLLED STUDY; ENDOSCOPIC MUCOSAL RESECTION; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOFREQUENCY ABLATION; REGISTER; TREATMENT OUTCOME; UNITED KINGDOM; ADENOCARCINOMA; CATHETER ABLATION; CLINICAL TRIAL; DISEASE COURSE; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PRECANCER; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TIME; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; CATHETER ABLATION; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROSPECTIVE STUDIES; REGISTRIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84940094321     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308501     Document Type: Article

References (45)

1. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005;129:1825-31.
2. Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer 2009;101:855-9.
3. Steevens J, Botterweck AA, Dirx MJ, et al. Trends in incidence of oesophageal and stomach cancer subtypes in Europe. Eur J Gastroenterol Hepatol 2010;22:669-78.
4. Reed PI, Johnston BJ. The changing incidence of oesophageal cancer. Endoscopy 1993;25:606-8.
5. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011;103:1049-57.
6. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365:1375-83.
7. de Jonge PJ, van BM, Looman CW, et al. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 2010;59:1030-6.
8. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-9.
9. Fernando HC, Luketich JD, Buenaventura PO, et al. Outcomes of minimally invasive esophagectomy (MIE) for high-grade dysplasia of the esophagus. Eur J Cardiothorac Surg 2002;22:1-6.
10. Nasr JY, Schoen RE. Prevalence of adenocarcinoma at esophagectomy for Barrett's esophagus with high grade dysplasia. J Gastrointest Oncol 2011;2:34-8.
11. Bartels H, Stein HJ, Siewert JR. Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer. Br J Surg 1998;85:840-4.
12. Bollschweiler E, Schroder W, Holscher AH, et al. Preoperative risk analysis in patients with adenocarcinoma or squamous cell carcinoma of the oesophagus. Br J Surg 2000;87:1106-10.
13. Holscher AH, Schroder W, Bollschweiler E, et al. How safe is high intrathoracic esophagogastrostomy?. Chirurg 2003;74:726-33.
14. Fernando HC, Murthy SC, Hofstetter W, et al. The Society of Thoracic Surgeons' practice guideline series: guidelines for the management of Barrett's esophagus with high-grade dysplasia. Ann Thorac Surg 2009;87:1993-2002.
15. Prasad GA, Wang KK, Buttar NS, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology 2007;132:1226-33.
16. Blazeby JM, Farndon JR, Donovan J, et al. A prospective longitudinal study examining the quality of life of patients with esophageal carcinoma. Cancer 2000;88:1781-7.
17. Djarv T, Lagergren J, Blazeby JM, et al. Long-term health-related quality of life following surgery for oesophageal cancer. Br J Surg 2008;95:1121-6.
18. Fitzgerald RC, di PM, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014;63:7-42.
19. Dunbar KB, Spechler SJ. The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett's esophagus: a systematic review. Am J Gastroenterol 2012;107:850-62.
20. Stein HJ, Feith M, Bruecher BL, et al. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 2005;242:566-73.
21. Liu L, Hofstetter WL, Rashid A, et al. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol 2005;29:1079-85.
22. Alvarez HL, Pouw RE, van Vilsteren FG, et al. Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. Endoscopy 2010;42:1030-6.
23. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009;360:2277-88.
24. Haidry RJ, Dunn JM, Butt MA, et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology 2013;145:87-95.
25. Ganz RA, Overholt BF, Sharma VK, et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U. S. Multicenter Registry. Gastrointest Endosc 2008;68:35-40.
26. Pasricha S, Bulsiewicz WJ, Hathorn KE, et al. Durability and predictors of successful radiofrequency ablation for Barrett's esophagus. Clin Gastroenterol Hepatol 2014;12:1840-7.e1.
27. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006;131:1392-9.
28. Participants in the Paris Workshop. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003;58(6, Supp 1):S3-S43.
29. Reid BJ, Blount PL, Feng Z, et al. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 2000;95:3089-96.
30. Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993;105:40-50.
31. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000;47:251-5.
32. Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012;143:336-46.
33. Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology 2011;141:460-8.
34. Phoa KN, Pouw RE, van Vilsteren FG, et al. Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology 2013;145:96-104.
35. Hirota WK, Loughney TM, Lazas DJ, et al. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999;116:277-85.
36. Spechler SJ, Zeroogian JM, Antonioli DA, et al. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994;344:1533-6.
37. Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol 2011;106:1447-55.
38. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy 2010;42:781-9.
39. Sharma P, Hawes RH, Bansal A, et al. Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett's oesophagus: a prospective, international, randomised controlled trial. Gut 2013;62:15-21.
40. Pohl J, Pech O, May A, et al. Incidence of macroscopically occult neoplasias in Barrett's esophagus: are random biopsies dispensable in the era of advanced endoscopic imaging? Am J Gastroenterol 2010;105:2350-6.
41. Pohl J, May A, Rabenstein T, et al. Comparison of computed virtual chromoendoscopy and conventional chromoendoscopy with acetic acid for detection of neoplasia in Barrett's esophagus. Endoscopy 2007;39:594-8.
42. Lightdale CJ, Kulkarni KG. Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer. J Clin Oncol 2005;23:4483-9.
43. Manner H, Pech O, Heldmann Y, et al. Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol 2013;11:630-5.
44. van Vilsteren FG, Pouw RE, Seewald S, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut 2011;60:765-73.
45. van Vilsteren FG, Alvarez HL, Pouw RE, et al. Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett's esophagus with early neoplasia: a prospective multicenter study. Endoscopy 2013;45:516-25.